We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-1.37%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.2B
AUM Growth
+$2.05B
(+17%)
Cap. Flow
+$2.63B
Cap. Flow
% of AUM
18.56%
Top 10 Holdings %
Top 10 Hldgs %
24.41%
Holding
915
New
139
Increased
425
Reduced
186
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$226M |
| 2 |
Microsoft
MSFT
|
+$205M |
| 3 |
Tesla
TSLA
|
+$83.2M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$65.6M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$64.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sociedad Química y Minera de Chile
SQM
|
+$60.4M |
| 2 |
Meta Platforms (Facebook)
META
|
+$39.1M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$36.9M |
| 4 |
Booking.com
BKNG
|
+$28M |
| 5 |
Stryker
SYK
|
+$25.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.77% |
| 2 | Technology | 24.47% |
| 3 | Financials | 9.64% |
| 4 | Consumer Discretionary | 7.95% |
| 5 | Industrials | 7.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Enovis
ENOV
$1.7B
| $906K | 0.01% |
+19,667
| New | +$1.07M |
|
702
Encompass Health
EHC
$11.5B
| $900K | 0.01% |
+19,907
| New | +$996K |
|
703
Castle Biosciences
CSTL
$725M
| $898K | 0.01% |
+34,423
| New | +$965K |
|
704
Aclaris Therapeutics
ACRS
$744M
| $886K | 0.01% |
+56,279
| New | +$887K |
|
705
Cerus
CERS
$585M
| $885K | 0.01% |
+245,791
| New | +$1.18M |
|
706
Alector
ALEC
$169M
| $871K | 0.01% |
+92,113
| New | +$996K |
|
707
Goldman Sachs
GS
$305B
| $867K | 0.01% |
2,958
+69
| +2% | +$22.4K |
|
708
Codexis
CDXS
$161M
| $866K | 0.01% |
+142,953
| New | +$1.15M |
|
709
Howmet Aerospace
HWM
$114B
| $866K | 0.01% |
27,982
| – | – |
|
710
Lantheus
LNTH
$6.68B
| $863K | 0.01% |
12,277
-19,082
| -61% | -$1.45M |
|
|
NVTA
711
DELISTED
Invitae Corporation
NVTA
| $859K | 0.01% |
+349,095
| New | +$1.06M |
|
712
EQT Corp
EQT
$32.3B
| $858K | 0.01% |
21,048
-111
| -0.5% | -$4.81K |
|
713
Opko Health
OPK
$1.23B
| $855K | 0.01% |
+452,348
| New | +$1.07M |
|
714
Atara Biotherapeutics
ATRA
$70.4M
| $849K | 0.01% |
+8,984
| New | +$1.01M |
|
|
TVRD
715
Tvardi Therapeutics
TVRD
$22.9M
| $848K | 0.01% |
+2,515
| New | +$911K |
|
716
NeoGenomics
NEO
$1.74B
| $847K | 0.01% |
+98,316
| New | +$976K |
|
|
SEM
717
DELISTED
Select Medical
SEM
| $847K | 0.01% |
+71,161
| New | +$1.01M |
|
718
Henry Schein
HSIC
$9.76B
| $846K | 0.01% |
+12,868
| New | +$956K |
|
719
American Homes 4 Rent
AMH
$12.2B
| $845K | 0.01% |
+25,747
| New | +$930K |
|
720
Myriad Genetics
MYGN
$502M
| $843K | 0.01% |
+44,157
| New | +$1.01M |
|
|
LSXMA
721
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $838K | 0.01% |
+29,965
| New | +$887K |
|
|
COWN
722
DELISTED
Cowen Inc. Class A Common Stock
COWN
| $834K | 0.01% |
+21,578
| New | +$785K |
|
|
BKI
723
DELISTED
Black Knight, Inc. Common Stock
BKI
| $831K | 0.01% |
+12,834
| New | +$845K |
|
724
Prelude Therapeutics
PRLD
$370M
| $830K | 0.01% |
+125,619
| New | +$847K |
|
725
Mesa Laboratories
MLAB
$559M
| $828K | 0.01% |
5,876
-2,221
| -27% | -$405K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2022 Portfolio in Review
As of Q3 2022, Candriam SCA held 915 positions worth $14.2B, up 17% from $12.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Candriam SCA deployed $2.63B of net new capital in Q3 2022, opening 139 new positions and adding to 425 existing holdings. Its largest new stake was Veru: 378,115 shares worth $43.6M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 34% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Sociedad Química y Minera de Chile, an estimated $60.4M trimmed.
- Candriam SCA's largest Q3 2022 buy was Veru: 378,115 shares worth $43.6M.
- Candriam SCA added most to Apple in Q3 2022, an estimated $226M increase.
- Candriam SCA's biggest Q3 2022 reduction was Sociedad Química y Minera de Chile, cutting an estimated $60.4M.
- Candriam SCA fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $36.9M.
- Candriam SCA's ten largest holdings make up 24% of its $14.2B portfolio in Q3 2022.
- Candriam SCA opened 139 new positions and closed 46 in Q3 2022.
- Candriam SCA's portfolio value rose 17% quarter-over-quarter to $14.2B.
Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.